The Norway study: plasma concentrations, efficacy, and adverse events.
In the Norwegian comparative trials of piroxicam and naproxen in osteoarthritis, conducted by Husby and co-workers and Rugstad et al, relationships between plasma drug concentrations and the following were examined: efficacy in patients with osteoarthritis; all adverse reactions; and serious adverse events, which included gastrointestinal ulceration or bleeding and congestive heart failure. Increased plasma concentrations were correlated with age and female sex, but efficacy, overall side effects, and serious adverse events were not correlated with increasing plasma levels.
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001835:Body Weight; D002986:Clinical Trials as Topic; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D009288:Naproxen / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D009664:Norway; D010003:Osteoarthritis / Q000188:drug therapy*; D010437:Peptic Ulcer / Q000139:chemically induced; D010894:Piroxicam / Q000009:adverse effects / Q000097:blood* / Q000627:therapeutic use; D012737:Sex Factors
D010894:Piroxicam; D009288:Naproxen